Welcome to our dedicated page for HeartBeam SEC filings (Ticker: BEAT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
HeartBeam, Inc. filings document material events for a Nasdaq-listed medical technology issuer with common stock under BEAT and warrants under BEATW. Its 8-K disclosures cover underwriting agreements and common-stock offering terms, emerging growth company status, and FDA-related correspondence for its 12-Lead ECG Synthesis Software.
These records also identify capital-structure changes and formal event disclosures tied to commercialization and regulatory development of HeartBeam's 3D ECG technology.
HeartBeam, Inc. announced a strategic reorganization and leadership transition centered on accelerating global adoption of its ambulatory ECG signal platform and improving capital efficiency. Chief Executive Officer and director Robert P. Eno will depart effective June 30, 2026, and is expected to move into a consulting role under his existing employment agreement, subject to a release of claims.
Founder and President Branislav Vajdic, Ph.D. will serve as principal executive officer effective July 1, 2026, while operations are aligned around focused implementation teams led by Dr. Vajdic and Executive Chairman Rich Ferrari. Director Mark Strome resigned from the Board on June 18, 2026; both his resignation and Mr. Eno’s departure are stated as not due to disputes or disagreements with the company.
The company highlights that its 3D ambulatory ECG platform, including 3D signal capture and 12‑lead ECG synthesis, has received FDA clearance for arrhythmia assessment, and it plans to continue clinical studies to expand its technology for heart attack and other cardiac conditions while targeting a meaningfully lower cost structure.
HeartBeam, Inc. reported new compensation arrangements for its President, Founder and Director, Dr. Branislav Vajdic. On June 15, 2026, the board approved a performance-based restricted stock unit (PRSU) award covering 2,800,000 restricted stock units under the 2022 Equity Incentive Plan.
The PRSUs vest only if both performance and service conditions are met. Performance milestones tied to operational, software, product-development and clinical study goals must be achieved within a period that ends on the earlier of one year from grant or just before a first Change in Control. Service-based vesting occurs in three equal annual installments over three years, with acceleration provisions upon a Change in Control or certain qualifying terminations. HeartBeam also entered into a Transaction Bonus Agreement with Dr. Vajdic, providing a bonus upon a Qualifying Change in Control based on achieving specified market capitalization and per-share price thresholds, paid generally in the same form as consideration to stockholders.
HeartBeam, Inc. is asking shareholders to vote at its virtual 2026 annual meeting on July 31, 2026 at 1:00 p.m. Eastern. Holders of 55,506,835 common shares as of June 5, 2026 can participate and have one vote per share.
Shareholders will elect nine directors, ratify CBIZ CPAs P.C. as independent auditor for 2026, and vote on amending the 2022 Equity Incentive Plan to add 3,000,000 shares, raising its capacity to 14,900,000 shares. The company states this would increase potential dilution by about 6%, on top of existing equity overhang of roughly 30% of common stock outstanding.
The proxy details board structure, committee responsibilities and independence, executive and director pay, and significant use of equity in 2025 in place of some cash salary and board fees to conserve cash while maintaining incentives aligned with shareholders.
HeartBeam, Inc. is soliciting proxies for its 2026 Annual Meeting to be held virtually on July 31, 2026. Shareholders will vote to elect nine directors, ratify CBIZ CPAs P.C. as auditor and consider an amendment to the 2022 Equity Incentive Plan to increase authorized shares by 3,000,000. The record date for voting is June 5, 2026 and there were 55,506,835 shares outstanding as of that date. The board recommends voting FOR each proposal. The amendment would raise the 2022 Plan cap from 11,900,000 to 14,900,000 shares; current awards include 501,488 RSUs and 9,979,532 options outstanding, and 6,542,707 shares remain available for grant as of the record date.
HeartBeam, Inc. reported another quarter of losses with no revenue and highlighted serious liquidity concerns. For the three months ended March 31, 2026, the company generated no revenue and recorded a net loss of $4.7 million, narrower than the $5.5 million loss a year earlier. Operating expenses were $4.7 million, with selling, general and administrative costs rising 17% and research and development falling 32% as product development and consulting spending declined.
Cash and cash equivalents were $2.0 million as of March 31, 2026, and management stated this is insufficient to fund operations for the next twelve months, raising “substantial doubt” about the company’s ability to continue as a going concern. Subsequent to quarter-end, HeartBeam completed an underwritten offering of 14,375,000 shares of common stock for gross proceeds of approximately $11.5 million. The company remains pre-revenue despite FDA clearances for its 3D ECG telehealth system and is beginning a limited commercial launch and multiple pilot studies, while expecting no material commercial revenue in 2026.
HeartBeam, Inc. director Richard Ferrari increased his stake by purchasing 57,500 shares of common stock at $0.80 per share. The buy was made in connection with HeartBeam’s underwritten public offering of 12,500,000 common shares, for which Titan Partners acted as sole bookrunner.
This amended Form 4 corrects Ferrari’s previously reported acquisition and total beneficial ownership. The original filing mistakenly showed 62,500 shares acquired; the correct figure is 57,500 shares. Following this transaction, Ferrari beneficially owns 286,636 shares of HeartBeam common stock directly.
HeartBeam, Inc. CFO Tim Cruickshank increased his stake by buying 31,250 shares of common stock at $0.80 per share. The purchase was made in connection with HeartBeam’s underwritten public offering of 12,500,000 shares of common stock.
The offering priced on April 14, 2026 and closed on April 16, 2026, with Titan Partners, a division of American Capital Partners, acting as sole bookrunner. After this transaction, Cruickshank directly owns 72,230 shares, including 23,333 RSUs that have vested.
HeartBeam, Inc. director Willem Elfrink reported an open-market purchase of common stock. On April 16, 2026, he bought 187,500 shares at $0.80 per share, bringing his direct holdings to 538,667 shares.
According to the footnote, these shares were purchased in connection with HeartBeam’s underwritten public offering of 12,500,000 shares of common stock, which priced on April 14, 2026 and closed on April 16, 2026, with Titan Partners acting as sole bookrunner.
HeartBeam, Inc. director-associated entity Open Book Healthcare purchased 31,250 shares of common stock in an open-market transaction on April 16, 2026, at $0.80 per share. The purchase was made in connection with HeartBeam’s underwritten public offering of 12,500,000 shares of common stock, which priced on April 14, 2026 and closed on April 16, 2026. Following this transaction, 31,250 shares are held indirectly for the benefit of Michael R. Jaff through Open Book Healthcare.
HeartBeam, Inc. director Branislav Vajdic made an open-market purchase of 31,250 shares of common stock at $0.80 per share. After this transaction, he directly owns 909,914 shares.
The shares were bought in connection with HeartBeam’s underwritten public offering of 12,500,000 common shares, for which Titan Partners, a division of American Capital Partners, acted as sole bookrunner. The offering priced on April 14, 2026 and closed on April 16, 2026.